Messerschmidt Addresses the Future of Cancer Vaccines in FiercePharma
Precision Oncology’s Gerry Messerschmidt, MD, talks with FiercePharma’s Eric Sagonowsky and predicts we’ll see licensed cancer vaccines in the next 2 to 3 years. (more…)
Managed Healthcare Executive Shares Results of Rapid Pulse Survey on Nonpayer Data
In the latest edition of Managed Healthcare Executive, Precision’s Ami Gopalan shares key insights from an exclusive Rapid Pulse survey. The findings shed light on how payers use nonpayer-generated data to make formulary decisions. (more…)
Precision’s Messerschmidt and Schafer Discuss Cost of New Gene Therapies With Managed Healthcare Executive
In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies. (more…)
Ethan Leder’s Puerto Rico Relief Efforts Shared by NPR
NPR describes the efforts of Precision Medicine Group cofounder Ethan Leder to deliver desperately needed medical and emergency supplies to Puerto Rico. (more…)
Ethan Leder Spearheads Effort to Deliver Medical and Emergency Supplies to Puerto Rico
Precision Medicine Group cofounder Ethan Leder is featured in the Johns Hopkins University publication HUB, detailing his recent efforts to help personally deliver desperately needed medical and emergency supplies to Puerto Rico in the aftermath of Hurricane Maria. (more…)
Q&A With Precision’s Scott Marshall in Drug Discovery & Development: Biomarkers Can Inform Early-Stage Clinical Trial Design
Precision for Medicine’s Scott Marshall, managing director, Translational Informatics & Diagnostics, participates in a Q&A with Drug Discovery & Development’s Ryan Bushey. Marshall outlines the benefits biomarkers can yield in early-stage trials.
To read the complete interview, click here.
David Parker Discusses CDx Development in Clinical OMICs
David Parker, SVP, Diagnostics Solutions, was interviewed along with a panel of experts on changes in CDx development in Clinical Omics. (more…)
GenomeWeb Reports on Epiontis Acquisition
GenomeWeb covers Precision for Medicine’s recent acquisition of Epiontis, summarizing Precision’s busy year of growth and highlighting the expanded capabilities now available to clients. (more…)
Precision for Medicine Acquires Epiontis—a Leading Immune Monitoring and Epigenetic Technology Service Provider
ADDITION OF BERLIN-BASED LAB EXPANDS PRECISION’S LARGE ARRAY OF IMMUNE MONITORING CAPABILITIES AND BOLSTERS GLOBAL FOOTPRINT
Bethesda, MD and Berlin, Germany – October 4th, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Berlin-based Epiontis GmbH, a next-generation European specialty laboratory providing immune monitoring services through a novel, patent-protected epigenetic platform. The acquisition adds Epiontis’s unique epigenetic technology and expertise to Precision’s robust suite of immune monitoring services for clinical trials, bringing additional value and capabilities to clients. It expands Precision’s growing global footprint and further positions the company as a scientific frontrunner in the rapidly expanding precision medicine space.
Precision Launches New All Access Newsletter for Market Access Leaders
Precision for Value is excited to be debuting a new publication– the Precision All Access Newsletter. All Access is an exclusive bi-monthly publication featuring key insights from our team of former payers intended specifically for market access leaders. (more…)